China BioPharma Issues Profile on TheAsianInvestor.com.

ISELIN, N.J. -- Techedge Inc. (OTCBB:TEDG) announced that China BioPharma, Ltd. has issued a company profile on Chinese investment website The Asian Investor.

Investors can view the company report by going to www.theasianinvestor.com

Peter Wang commented, "The Company is pleased to make this first step in launching our investor awareness campaign for China BioPharma, Ltd., as one of China's largest non-government owned human vaccine production companies. The Company is involved in the research and production of human vaccines for highly contagious diseases such as Bird Flu, EHF, and a number of Influenza viruses."

About China BioPharma

China BioPharma, which owns majority rights to Tianyuan Bio-pharmaceutical Co., Ltd., established in 1989, is one of China's largest non-governmental owned vaccine research manufacturers and is the first in China confirmed to GMP standard. The company's current products consist of vaccines for epidemic hemorrhagic fever (EHF) and influenza with high reputation and market-occupying rate. The vaccines for both epidemic hemorrhagic fever and influenza virus have been awarded the National New Product Prize and National Tech Progress Prize.

Tianyuan Bio-pharmaceutical Co., Ltd. plans to establish the production of 3 to 5 new products to its research portfolio of vaccines, with 3 major in the series of aspects of bacterial, virus, and viral vaccines, having already accomplished a batch of technical achievements with autonomous intellectual property. With its recently completed production facility that is the largest and best human-vaccine production facility in China, it is also the nation's main vaccine production base whenever there is an epidemic disease outbreak in the region, such as with SARS, or Avian H5N1 Influenza (bird flu). The company currently has around 140 employees.

For fiscal year 2005, Tianyuan Bio-pharmaceutical Co., Ltd. realized $9 million in sales, with a net profit of $1.5 million for the year, un-audited. The company is in the final process of completing independent audits to US GAAP standards, which should be available for public review shortly.

About Techedge Inc.

The Company has recently repositioned itself to focus at opportunities in the fast growing bio-pharmaceutical sector in China. Techedge Inc. recent acquisition of China BioPharma Limited (CBP), a Cayman Island company, which has majority ownership rights to Tianyuan Bio-pharmaceuticals Co. Ltd., is based out of Zhejiang Province, and the acquisition is pending Chinese government's final approval.

For more information on their current vaccines please visit www.ty-pharm.com

FORWARD-LOOKING STATEMENT DISCLAIMER

Some of the statements made in this press release discuss future events and developments, including our future business strategy and our ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history.